Design of Experiments (DoE)‐Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose‐to‐Brain Delivery

Why It Matters

The platform addresses the long‑standing challenge of delivering oxytocin efficiently to the brain, potentially increasing clinical efficacy for autism without peripheral side effects. It also demonstrates a scalable nanotechnology that could be adapted for other neuropeptides.

Key Takeaways

• PEGylated PLGA nanoparticles achieve ~100 nm size.
• Drug loading reaches up to 3.5% w/w.
• In vivo study shows higher brain uptake, lower peripheral exposure.
• Sustained release exceeds 40% at 24 h.
• Behavioral assay confirms retained oxytocin activity.

Pulse Analysis

Intranasal delivery has emerged as a non‑invasive route to bypass the blood‑brain barrier, yet peptide therapeutics like oxytocin suffer from rapid clearance and limited mucosal penetration. Traditional sprays rely on passive diffusion, resulting in variable brain exposure and peripheral side effects that diminish clinical outcomes for autism spectrum disorder. By encapsulating oxytocin within an FDA‑approved PLGA matrix and adding a PEG corona, researchers create a stealthy carrier that navigates the viscous nasal mucus, prolongs residence time, and shields the peptide from enzymatic degradation, thereby addressing the core pharmacokinetic hurdles.

The study employed a systematic design‑of‑experiments (DoE) methodology to fine‑tune critical quality attributes such as particle size, polydispersity index, zeta potential, and drug loading. Optimized nanoparticles measured between 93 and 116 nm, exhibited a modest negative surface charge (‑21 to ‑33 mV), and achieved loading efficiencies up to 3.5 % w/w. In vitro release profiles demonstrated a controlled release, with more than 40 % of oxytocin liberated after 24 hours and 58 % after 72 hours, while diffusion assays confirmed superior mucus permeation compared with non‑PEGylated counterparts. These physicochemical characteristics suggest a robust platform capable of consistent dosing and scalable manufacturing.

Translating these findings in vivo, radiolabeled oxytocin‑NP‑PEG administered intranasally to mice resulted in pronounced accumulation in the olfactory bulb and frontal cortex, regions directly linked to social cognition. Systemic distribution to blood and liver was markedly reduced, mitigating peripheral exposure. Importantly, treated animals displayed increased self‑grooming behavior, a proxy for preserved oxytocin activity, indicating that the nanocarrier does not compromise pharmacodynamics. This convergence of targeted delivery, sustained release, and maintained bioactivity positions PEGylated PLGA nanoparticles as a promising vector for neuropeptide therapeutics, potentially accelerating the pipeline for brain‑focused treatments across a spectrum of psychiatric disorders.